Advanced search
Publication Cover
Future Oncology Volume 20, 2024 - Issue 7
Submit an article Journal homepage
97
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Response to First-Line Pembrolizumab in Metastatic KRAS-Mutated Non-Small-Cell Lung Cancer

Sabrina Rossi1 Medical Oncology & Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8853-0775
ORCID Icon,
Arianna Pagliaro1 Medical Oncology & Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy;4 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 20072, Italy
,
Giovanna Finocchiaro1 Medical Oncology & Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy
,
Arianna Marinello1 Medical Oncology & Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy;4 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 20072, Italy
,
Laura Giordano2 Biostatistic Unit, IRCSS Humanitas Research Hospital – Humanitas Cancer Center, Rozzano, Milan, 20089, Italy
,
Emilio Bria3 U.O.C. Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, Italy
,
Alessio Stefani3 U.O.C. Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, Italy
,
Antonio Vitale3 U.O.C. Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, ItalyORCID Iconhttps://orcid.org/0000-0003-1582-8006
ORCID Icon,
Luca Toschi1 Medical Oncology & Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy
,
Ettore D’Argento3 U.O.C. Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, 00168, Italy
&
Armando Santoro1 Medical Oncology & Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy;4 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 20072, Italy
 show all
Pages 373-380 | Received 08 Nov 2023, Accepted 20 Feb 2024, Published online: 06 Mar 2024

References

  • De Mello RAB , VoscaboinikR, LucianoJVPet al. Immunotherapy in patients with advanced non-small cell lung cancer lacking driver mutations and future perspectives. Cancers (Basel)14(1), 122 (2021).
  • Gandhi L , Rodríguez-AbreuD, GadgeelSet al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med.378(22), 2078–2092 (2018).
  • Paz-Ares L , LuftA, VicenteDet al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med.379(21), 2040–2051 (2018).
  • Garassino MC , GadgeelS, NovelloSet al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic NSCLC. JTO Clin. Res. Rep.4(1), 100431 (2022).
  • Sonehara K , OzawaR, HamaMet al. Predictive factors associated with long-term response to combination immunotherapy in patients with untreated advanced non-small-cell lung cancer: a multicenter retrospective study. Oncology101(7), 425–434 (2023).
  • Xu M , HaoY, ZengXet al. Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer. J. Thorac. Dis.15(4), 1648–1657 (2023).
  • Liu SM , ZhengMM, PanYet al. Emerging evidence and treatment paradigm of non-small cell lung cancer. J. Hematol. Oncol.16(1), 40 (2023).
  • De Mello RAB , VoscaboinikR, LucianoJVPet al. Immunotherapy in patients with advanced non-small cell lung cancer lacking driver mutations and future perspectives. Cancers (Basel)14(1), 122 (2021).
  • Bungaro M , NovelloS, PassigliaF. Targeting KRAS p. G12C mutation in advanced non-small cell lung cancer: a new era has begun. Curr. Treat. Options. Oncol.23(12), 1699–1720 (2022).
  • Mok TSK , LopesG, ChoBCet al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann. Oncol.34(4), 377–388 (2023).
  • Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur. J. Cancer45(2), 228–247 (2009).
  • Chen N , FangW, LinZet al. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol. Immunother.66(9), 1175–1187 (2017).
  • Liu C , ZhengS, JinRet al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett.470, 95–105 (2020).
  • Sun L , HsuM, CohenRBet al. Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer. JAMA Oncol.7(6), 937–939 (2021).
  • Nakajima EC , RenY, VallejoJJet al. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. J. Clin. Oncol.40(suppl. 16), 9001 (2022).
  • Noordhof AL , DamhuisRAM, HendriksLELet al. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. Lung Cancer155, 163–169 (2021).
  • Herbst RS , LopesG, KowalskiDMet al. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042. Ann. Oncol.30, xi63–xi64 (2019).
  • Dong ZY , ZhongWZ, ZhangXCet al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin. Cancer Res.23, 3012–3024 (2017).
  • Nakajima EC , DreznerN, LiXet al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin. Cancer Res.28(8), 1482–1486 (2022).
  • Ou SI , JännePA, LealTAet al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS G12C solid tumors (KRYSTAL-1). J. Clin. Oncol.40(23), 2530–2538 (2022).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.